Welcome to the Second 2016 Issue of The CLL Tribune
We are a data driven society and it is only with good data that we make progress.
That is particularly true when we are dealing with a largely incurable cancer, our CLL.
That’s why we at the CLL Society are so pro clinical trials- more information to help move us closer to a cure.
And that’s why we are generating our own data through surveys. We can use this information to influence decision makers about trial design, drug development and what matters to us patients.
And that’s why when I spoke at the European Hematology Association Congress in Copenhagen, more than a thousand hematologists packed the auditorium and spilt out into the halls to hear what you had to say in our surveys and afterwards, to push me for more data.
So thanks for all your help. We couldn’t do it without you. Please take a moment to complete our survey about CLL experts here.
As I have said many times, we are all this together.
This CLL Tribune is full of “expert” advice from both patients and doctors on the frontlines. We also introduce John Huber, our newest Board Member who retired from running the Aplastic Anemia and MDS International Foundation last summer and is now helping us here in many ways including with his article [provide link to article] on being a novice patient.
If you know of someone who could benefit from learning more about CLL, please invite them to visit cllsociety.org and sign up to receive the newsletter and email alerts. Feedback and suggestions for future newsletter topics are always welcome and can be emailed to firstname.lastname@example.org. We hope you enjoy our June 2016 issue. Keep on the lookout for our next one in three months!
I hope you find much of interest and value.
By Richard Furman, MD
Dr. Richard Furman of Weill-Cornell Medical College answers readers’ questions submitted to the Q1 2016 issue of The CLL Tribune…Read more
By Brian Koffman, MD and Jeffrey Jones, MD, MPH
In the first half of our video interview from the 2016 European Hematology Association meeting held in Copenhagen, Denmark in June…Read The Interview
We’d like to thank the supporters of The CLL Tribune:
- Genentech/Biogen Idec
- Sunesis Pharmaceuticals
- TEVA Pharmaceuticals
- TG Therapeutics
The CLL Society does not provide medical advice or endorsements. Unless explicitly stated otherwise, all content in the CLL Tribune is the opinion or information of its author, not the CLL Society. This newsletter is for reference and educational purposes only and is not a substitute for medical advice. We do not guarantee the accuracy of any of the materials. Always contact your own doctor or other professional healthcare provider if you have any questions concerning your or your family’s health. Everyone’s circumstances are different.